MaxCyte Inc
NASDAQ:MXCT
MaxCyte Inc
Total Current Assets
MaxCyte Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Total Current Assets
$171.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
48%
|
CAGR 10-Years
40%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Current Assets
$28.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Current Assets
$12.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Total Current Assets
$2.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Current Assets
$4.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Current Assets
$6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Total Current Assets?
Total Current Assets
171.7m
USD
Based on the financial report for Dec 31, 2024, MaxCyte Inc's Total Current Assets amounts to 171.7m USD.
What is MaxCyte Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
40%
Over the last year, the Total Current Assets growth was -10%. The average annual Total Current Assets growth rates for MaxCyte Inc have been -14% over the past three years , 48% over the past five years , and 40% over the past ten years .
